Cu-DOTA-ECL1i
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Washington University School of Medicine
Overview
Cu-DOTA-ECL1i is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
Cu-DOTA-ECL1i clinical trials
Explore related
Medical disclaimer. This page summarizes research about Cu-DOTA-ECL1i for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.